Acorda Therapeutics (ACOR) Announces Publication of New Data on Impact of Mobility Impairment Due to Multiple Sclerosis
5/21/2013 10:05:55 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
ARDSLEY, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics (NASDAQ: ACOR) today announced new research findings that show a loss of mobility due to multiple sclerosis (MS) has a negative impact on work productivity and patient-reported perceptions of health. The paper, published in PLoS ONE, estimated that the total costs of this lost productivity, often referred to as indirect costs, exceed $30,000 per person with MS, per year.
Help employers find you! Check out all the jobs and post your resume.
comments powered by